1. Modulation of epithelial-to-mesenchymal cancerous transition by natural products
   Lei Zhang et al, 2015, Fitoterapia CrossRef
2. TGF-β1 promotes the migration and invasion of bladder carcinoma cells by increasing fascin1 expression
   Naiwen Zhang et al, 2016, Oncology Reports CrossRef
3. Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells
   Wenjing Li et al, 2017, Oncology Letters CrossRef
4. Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells
   Ughur Aghamaliyev et al, 2019, European Surgical Research CrossRef
5. Chemotherapy-induced metastasis: mechanisms and translational opportunities
   George S. Karagiannis et al, 2018, Clinical & Experimental Metastasis CrossRef
6. Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks
   Javier Vaquero et al, 2017, Journal of Hepatology CrossRef
7. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
   Milad Ashrafizadeh et al, 2021, Biomedicine & Pharmacotherapy CrossRef
8. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer
   Roberto Filippi et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
9. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
   Chiara Varamo et al, 2019, Cancers CrossRef
10. microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway
    Pengfei Qiao et al, 2015, BMC Cancer CrossRef
11. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives
    Hidehiro Tajima et al, 2017, Oncology Letters CrossRef
12. Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma
    Mingwen Jiao et al, 2020, International Journal of Oncology CrossRef
13. Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
    Annamaria Massa et al, 2022, Frontiers in Oncology CrossRef
14. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer
    Hidehiro Tajima et al, 2018, Molecular and Clinical Oncology CrossRef
15. Epithelial-mesenchymal transition as a target for botanicals in cancer metastasis
    Bahare Salehi et al, 2019, Phytomedicine CrossRef
16. Neoadjuvant chemotherapy with gemcitabine‑based regimens improves the prognosis of node positive resectable pancreatic head cancer
    Hidehiro Tajima et al, 2019, Molecular and Clinical Oncology CrossRef
17. Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort
    Somayye Taghvaei et al, 2021, Frontiers in Pharmacology CrossRef
18. Neoadjuvant therapy for resectable pancreatic cancer: a narrative review
    Chengfang Wang et al, 2022, Journal of Pancreatology CrossRef
19. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
    Simone Brivio et al, 2015, Journal of Clinical Medicine CrossRef
20. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer
    Hidehiro Tajima et al, 2017, Molecular and Clinical Oncology CrossRef